查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
粒子治療系統的全球市場-2022-2029
市場調查報告書
商品編碼
1140686

粒子治療系統的全球市場-2022-2029

Global Particle Therapy System Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球癌症患者數量的增加正在推動粒子治療系統市場的發展。

根據美國國家癌症研究所的數據，預計 2020 年美國將診斷出 180 萬例新的癌症病例，並將登記 606,520 例死於該疾病的病例。到 2020 年，大約 43.0% 的男性確診癌症將是前列腺癌、結直腸癌或肺癌。對於女性來說，肺癌、乳腺癌和結直腸癌是最常見的三種癌症，約佔女性新診斷癌症的 50%。隨著癌症患者數量的增加，對治療系統的需求將增加，在預測期內為粒子治療系統市場提供增長機會。

此外，消費者對粒子治療系統的認識不斷提高，也推動了市場的增長。此外，與傳統放射療法相比，質子療法的優勢使患者轉向質子療法。多項研究表明，與標準放射治療相比，質子治療可能會引起短期和長期副作用，包括減少繼發性腫瘤發展的機會和提高生活質量。因此，全球範圍內從傳統療法向質子療法的轉變正在增加。

地理滲透。

北美是預測期內的主要地區。

該研究按地區分析了全球市場的粒子治療系統市場，包括北美、南美、歐洲、亞太地區、中東和非洲。

就價值和數量而言，北美佔全球粒子治療系統市場的最大份額，其次是歐洲和亞太地區。2022年北美多重檢測市場將由美國主導。該市場主要由美國技術先進的醫療保健基礎設施和政府機構不斷增加的資金推動。

此外，預計亞太地區的粒子治療系統市場在預測期內將以最快的複合年增長率增長。在亞太地區，由於患者人數的增加、醫療基礎設施的快速發展以及製藥公司研發活動的顯著增加，預計中國將主導市場。

競爭格局。

由於粒子治療系統品牌眾多，粒子治療系統市場競爭激烈。主要的粒子治療系統公司包括 Danfysik A/S、Advanced Oncotherapy PLC、Hitachi, Ltd.、Optivus Proton Therapy, Inc、Mevion Medical Systems, Inc、Provision Healthcare, LLC、Protom International, Inc、Ion Beam Applications Sa (IBA)、 Sumitomo Heavy Industries, Ltd.、Varian Medical Systems, Inc.、HD Biosciences Co, Ltd.、Hitachi, Ltd. 和Toshiba。決定性的參與者正在為粒子治療系統市場的全球增長採用新產品和服務的推出和擴張戰略。2021年6月，Advanced Oncotherapy簽訂合同，以1.07億美元提供三間LIGHT系統治療室。本合同金額適用於輕型設備的採購、安裝及長期維修保修合同。該系統將安裝在瑞士的質子治療設施中。2022年8月，用於治療癌症患者的質子粒子束治療的主要製造商和供應商Mevion Medical Systems向中國同濟醫科大學同濟醫院交付了質子束治療系統“MEVION S250i”。質子治療優於放射治療，因為它減少了對周圍健康組織和敏感器官的不必要輻射暴露。質子束療法已被用於減少有害輻射，並且粒子療法的採用正在增加。

COVID-19 的影響。它對全球粒子治療系統市場產生了負面影響。

據估計，COVID-19 大流行將抑制預測期內粒子治療系統市場的增長。在開發 COVID-19 疫苗的同時，由於採用率下降，市場在 2020 年出現了小幅下滑。政府提供擇期手術指南，以減輕衛生系統的壓力、減少疾病傳播並節省個人防護設備。因此，粒子治療系統市場在 2020 年出現溫和下滑。在大流行期間，全球癌症負擔增加了 20%。這可能是由於診斷和治療程序的推遲。幾乎所有癌症治療中心都提供粒子治療緊急服務，在大流行期間到中心治療的患者人數有所下降。由於封鎖導致的製造設施關閉擾亂了供應鏈，臨床試驗的招聘減少對 Covid 大流行中整個粒子治療系統市場的增長產生了負面影響。

全球粒子治療系統市場報告提供了大約 77 個市場數據表、71 個數字和 170 頁的結構。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

  • 按產品/服務劃分的市場細分
  • 按類型劃分的市場細分
  • 按系統劃分的市場細分
  • 按癌症類型劃分的市場細分
  • 按應用劃分的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
    • 促進者
      • 癌症患病率增加
      • 在臨床試驗中越來越多地採用粒子療法
    • 抑製劑
      • 治療的可負擔性和可及性
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措
  • 概括

第 7 章按產品/服務分類

  • 機器
  • 服務

第 8 章 按類型

  • 質子治療
  • 重離子放療

第 9 章 按系統

  • 多房間系統
  • 單人房

第10章按癌症類型

  • 前列腺癌
  • 肺癌
  • 乳腺癌
  • 兒童癌症
  • 其他（頭頸癌）

第 11 章 按申請

  • 治療用途
  • 調查使用

第12章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第十三章 競爭格局

  • 競爭情景
  • 市場定位/市場份額分析
  • 併購分析

第十四章公司簡介

  • Danfysik A/S
    • 公司簡介
    • 產品/服務組合和描述
    • 主要亮點
    • 財務概覽
  • 先進的腫瘤治療 PLC
  • Hitachi, Ltd.
  • Optivus Proton Therapy, Inc.
  • Mevion Medical Systems, Inc.
  • Provision Healthcare, LLC
  • Protom International, Inc.
  • Ion Beam Applications Sa（IBA）
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.（List Not Exhaustive）

第 15 章 重要注意事項

第 16 章 數據管理

簡介目錄
Product Code: DMHCIT3083

Market Overview

Particle Therapy System Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.6% during the forecast period (2022-2029).

Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. Proton Therapy System provides cancer therapy via pencil beam spot scanning technology. Particle therapy could minimize the extent and severity of normal tissue injury. Particle therapy is one of the cutting-edge areas of external beam radiotherapy. Growth in the particle therapy market is primarily driven by factors such as the several advantages offered by particle therapy over photon therapy, the growing prevalence of cancer, the increasing adoption of particle therapy in clinical trials, and the rising number of particle therapy centers worldwide.

Market Dynamics: Rising number of cancer cases globally drives particle therapy systems market.

According to the National Cancer Institute, in 2020, an estimated 1.8 million new cancer cases will be diagnosed in the US, and 606,520 mortalities will be registered from the disease. In 2020, prostate, colorectal, and lung cancers accounted for around 43.0% of all cancers diagnosed in men. For women, the three most common cancers are lung, breast, and colorectal, accounting for around 50% of all new cancer diagnoses in women. With the rising cancer cases, the demand for therapy systems will increase, offering growth opportunities to the particle therapy system market during the forecast period.

Moreover, increasing consumers' awareness of particle therapy systems drives the market growth. Also, the advantages of proton therapy over conventional radiotherapy divert patients towards proton therapy. Several types of research have stated that proton therapy can cause short- and long-term side effects compared to standard radiation therapy, which includes reducing the chances of secondary tumors occurrence and improving quality of life. Therefore, the transition from conventional therapy to proton therapy is increasing globally.

Market Segmentation: The treatment segment accounted for the highest share in global particle therapy system market.

Based on the application, the particle therapy system market has been classified into treatment and research applications.

The treatment application segment dominated the total market in 2019. This dominance is backed by its growing use in discovery, manufacturing, and drug development. Moreover, the rising adoption of particle therapy systems in various cancer diagnoses, including immune system diseases, bone marrow diseases, and other infectious diseases, are driving the market.

Based on the type, the particle therapy system market has been classified into proton therapy systems and heavy ion therapy.

The proton therapy segment dominated the global particle therapy system market in the forecast period, backed by several advantageous factors, such as the high degree of precision, reduced side effects associated with proton therapy, and shorter treatment time. These factors are accelerating the growth of the proton therapy market, a transition from heavy ion therapy.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the particle therapy system market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America dominates the global particle therapy system market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American multiplex assay market in 2022. The market is mainly driven by the presence of well-developed technologically advanced healthcare infrastructure in the US coupled with increased funding by government agencies.

Moreover, Asia Pacific is projected to grow at the fastest CAGR in the particle therapy system market during the forecast period. China is estimated to dominate the Asia Pacific market due to the increase in patient population, rapidly developing healthcare infrastructure and significant rise in R&D activities in pharmaceutical companies in the region.

Competitive Landscape:

The particle therapy system market is highly competitive, owing to the large presence of particle therapy system brands. The key particle therapy system players include Danfysik A/S, Advanced Oncotherapy PLC, Hitachi, Ltd., Optivus Proton Therapy, Inc., Mevion Medical Systems, Inc., Provision Healthcare, LLC, Protom International, Inc., Ion Beam Applications Sa (IBA), Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc., HD Biosciences Co., Ltd. The crucial players are adopting new Product & Service launches and expansion strategies for global growth in the particle therapy system market. In June 2021, Advanced Oncotherapy signed a deal to provide three LIGHT system treatment rooms for US$107mln. This contract value is used for the purchase of light equipment, installation and long-term maintenance and warranty agreement. This system is installed in a proton therapy center in Switzerland. August 2022, Mevion Medical Systems, a leading manufacturer and supplier of proton particle therapy for the treatment of cancer patients delivered the MEVION S250i Proton therapy system to Tongji Hospital of Tongji Medical College, China. Proton therapy is superior to radiation therapy; that can reduce the unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. The adoption of particle therapy is increasing due to the adoption of proton particle therapy to reduce harmful radiation.

COVID-19 Impact: Negative impact on the global particle therapy system market.

The COVID-19 pandemic is estimated to derail the particle therapy system market growth during the forecast period. The market has seen a modest decrease in 2020, backed by the decline in its adoption while developing vaccines for COVID-19. Governments have provided guidelines for elective surgeries to reduce the strain on the healthcare system, decrease disease transmission, and conserve personal protective equipment. Therefore, a modest downfall was witnessed by the particle therapy system market in 2020. The global cancer burden increased by 20% during the pandemic. It can be attributed to the postponement of diagnosis and treatment procedures. Particle therapy emergency services were available in almost all cancer treatment centers, and the number of patients visiting centers for treatment has reduced during the pandemic. Closed manufacturing facilities due to lockdowns have disrupted supply chains, and reduced recruitments for clinical trials negatively impacted the growth of the overall particle therapy devices market in the Covid Pandemic.

The global particle therapy system market report would provide an access to approximately 77 market data tables, 71 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product & Services
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by System
  • 3.4. Market Snippet by Cancer Type
  • 3.5. Market Snippet by Application
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Cancer
      • 4.1.1.2. Growing Adoption of Particle Therapy in Clinical Trials
    • 4.1.2. Restraints:
      • 4.1.2.1. Affordability and Accessibility of Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Services

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services Segment
  • 7.3. Market Attractiveness Index, By Product & Services Segment
    • 7.3.1. Equipment*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Services

8. By Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 8.3. Market Attractiveness Index, By Type Segment
    • 8.3.1. Proton Therapy*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Heavy Ion Therapy

9. By System

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System Segment
  • 9.3. Market Attractiveness Index, By System Segment
    • 9.3.1. Multi-Room System*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Single-Room System

10. By Cancer Type

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type Segment
  • 10.3. Market Attractiveness Index, By Cancer Type Segment
    • 10.3.1. Prostate Cancer*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Lung Cancer
    • 10.3.3. Breast Cancer
    • 10.3.4. Pediatric Cancer
    • 10.3.5. Others (Head and Neck Cancer)

11. By Application

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3. Market Attractiveness Index, By Application
    • 11.3.1. Treatment Application*
      • 11.3.1.1. Introduction
      • 11.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 11.3.2. Research Application

12. By Region

  • 12.1. Introduction
  • 12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 12.3. Market Attractiveness Index, By Region
  • 12.4. North America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. U.S.
      • 12.4.8.2. Canada
      • 12.4.8.3. Mexico
  • 12.5. Europe
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. Germany
      • 12.5.8.2. U.K.
      • 12.5.8.3. France
      • 12.5.8.4. Italy
      • 12.5.8.5. Spain
      • 12.5.8.6. Rest of Europe
  • 12.6. South America
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.6.8.1. Brazil
      • 12.6.8.2. Argentina
      • 12.6.8.3. Rest of South America
  • 12.7. Asia Pacific
    • 12.7.1. Introduction
    • 12.7.2. Key Region-Specific Dynamics
    • 12.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.7.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.7.8.1. China
      • 12.7.8.2. India
      • 12.7.8.3. Japan
      • 12.7.8.4. Australia
      • 12.7.8.5. Rest of Asia Pacific
  • 12.8. Middle East and Africa
    • 12.8.1. Introduction
    • 12.8.2. Key Region-Specific Dynamics
    • 12.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.8.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Danfysik A/S*
    • 14.1.1. Company Overview
    • 14.1.2. Product & Services Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Advanced Oncotherapy PLC
  • 14.3. Hitachi, Ltd.
  • 14.4. Optivus Proton Therapy, Inc.
  • 14.5. Mevion Medical Systems, Inc.
  • 14.6. Provision Healthcare, LLC
  • 14.7. Protom International, Inc.
  • 14.8. Ion Beam Applications Sa (IBA)
  • 14.9. Sumitomo Heavy Industries, Ltd.
  • 14.10. Varian Medical Systems, Inc. (List Not Exhaustive)

15. Premium Insights

16. DataM Intelligence

  • 16.1. Appendix
  • 16.2. About Us and Services
  • 16.3. Contact Us